Irvine M - Search Results

1

The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma.

Lim SY, Shklovskaya E, Lee JH, Pedersen B, Stewart A, Ming Z, Irvine M, Shivalingam B, Saw RPM, Menzies AM, Carlino MS, Scolyer RA, Long GV, Rizos H. Lim SY, et al. Among authors: irvine m. Nat Commun. 2023 Mar 18;14(1):1516. doi: 10.1038/s41467-023-36979-y. Nat Commun. 2023. PMID: 36934113 Free PMC article.

2

Protein kinase inhibitor responses in uveal melanoma reflects a diminished dependency on PKC-MAPK signaling.

Park JJ, Stewart A, Irvine M, Pedersen B, Ming Z, Carlino MS, Diefenbach RJ, Rizos H. Park JJ, et al. Among authors: irvine m. Cancer Gene Ther. 2022 Oct;29(10):1384-1393. doi: 10.1038/s41417-022-00457-2. Epub 2022 Mar 29. Cancer Gene Ther. 2022. PMID: 35352024 Free PMC article.

3

Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.

Carlino MS, Fung C, Shahheydari H, Todd JR, Boyd SC, Irvine M, Nagrial AM, Scolyer RA, Kefford RF, Long GV, Rizos H. Carlino MS, et al. Among authors: irvine m. Clin Cancer Res. 2015 Jan 1;21(1):98-105. doi: 10.1158/1078-0432.CCR-14-0759. Epub 2014 Nov 4. Clin Cancer Res. 2015. PMID: 25370473

4

Oncogenic PI3K/AKT promotes the step-wise evolution of combination BRAF/MEK inhibitor resistance in melanoma.

Irvine M, Stewart A, Pedersen B, Boyd S, Kefford R, Rizos H. Irvine M, et al. Oncogenesis. 2018 Sep 20;7(9):72. doi: 10.1038/s41389-018-0081-3. Oncogenesis. 2018. PMID: 30237495 Free PMC article.

5

Durable Responses to Anti-PD1 and Anti-CTLA4 in a Preclinical Model of Melanoma Displaying Key Immunotherapy Response Biomarkers.

Shklovskaya E, Pedersen B, Stewart A, Simpson JOG, Ming Z, Irvine M, Scolyer RA, Long GV, Rizos H. Shklovskaya E, et al. Among authors: irvine m. Cancers (Basel). 2022 Oct 3;14(19):4830. doi: 10.3390/cancers14194830. Cancers (Basel). 2022. PMID: 36230753 Free PMC article.

6

Predicting functional significance of cancer-associated p16(INK4a) mutations in CDKN2A.

McKenzie HA, Fung C, Becker TM, Irvine M, Mann GJ, Kefford RF, Rizos H. McKenzie HA, et al. Among authors: irvine m. Hum Mutat. 2010 Jun;31(6):692-701. doi: 10.1002/humu.21245. Hum Mutat. 2010. PMID: 20340136

7

p14ARF regulates E2F-1 ubiquitination and degradation via a p53-dependent mechanism.

Rizos H, Scurr LL, Irvine M, Alling NJ, Kefford RF. Rizos H, et al. Among authors: irvine m. Cell Cycle. 2007 Jul 15;6(14):1741-7. doi: 10.4161/cc.6.14.4428. Epub 2007 May 10. Cell Cycle. 2007. PMID: 17630509

8

IGFBP7 is not required for B-RAF-induced melanocyte senescence.

Scurr LL, Pupo GM, Becker TM, Lai K, Schrama D, Haferkamp S, Irvine M, Scolyer RA, Mann GJ, Becker JC, Kefford RF, Rizos H. Scurr LL, et al. Among authors: irvine m. Cell. 2010 May 14;141(4):717-27. doi: 10.1016/j.cell.2010.04.021. Cell. 2010. PMID: 20478260 Free article.

9

Amino terminal hydrophobic import signals target the p14(ARF) tumor suppressor to the mitochondria.

Irvine M, Philipsz S, Frausto M, Mijatov B, Gallagher SJ, Fung C, Becker TM, Kefford RF, Rizos H. Irvine M, et al. Cell Cycle. 2010 Feb 15;9(4):829-39. doi: 10.4161/cc.9.4.10785. Epub 2010 Mar 2. Cell Cycle. 2010. PMID: 20107316

10

Selective loss of wild-type p16(INK4a) expression in human nevi.

Scurr LL, McKenzie HA, Becker TM, Irvine M, Lai K, Mann GJ, Scolyer RA, Kefford RF, Rizos H. Scurr LL, et al. Among authors: irvine m. J Invest Dermatol. 2011 Nov;131(11):2329-32. doi: 10.1038/jid.2011.197. Epub 2011 Jul 7. J Invest Dermatol. 2011. PMID: 21734716 Free article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

241 results

Search Page